Evidence map›Paper›PMID 41717405›Full record

ReviewFrontiers in oncology2026

Fatal hemangioblastoma: a case report and literature review.

Wenjie Zhang, Xu Zhang, Chang Ge, Cao Yang, Rui Li, Jingxuan Xu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjie Zhang *Neuroscience Center, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Xu Zhang *Neuroscience Center, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Chang GeNeuroscience Center, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Cao YangNeuroscience Center, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Rui LiNeuroscience Center, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Jingxuan XuNeuroscience Center, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hemangioblastoma (HB) is a benign tumor of the central nervous system (CNS), typically associated with a favorable prognosis following aggressive surgical resection. Spontaneous rupture and bleeding of these tumors are exceptionally rare, with only a small number of fatal cases reported. The rarity of such cases has impeded reliable epidemiological studies, underscoring the need to investigate the risk factors associated with HB-related mortality. Case Report: A patient presented with a 12-hour history of headache and rapidly became comatose approximately 30 minutes after admission. Neuroimaging revealed a large, solitary tumor located in the cerebellar vermis, medulla, and C1 segment of the spinal cord, with spontaneous rupture resulting in severe intracerebral hemorrhage. Despite emergency resuscitation and subsequent surgical resection, the patient unfortunately succumbed to their condition. Pathological examination confirmed the diagnosis of hemangioblastoma. Result: A review of studies published after 2000 identified 21 articles meeting the inclusion criteria, plus one additional case from our hospital, resulting in a total of 30 patients. A summary analysis was conducted on demographic information, age at first diagnosis, time to recurrence, overall survival, maximum tumor diameter, tumor locations (initial and recurrent), tumor texture, presence of VHL, surgical intervention, hemorrhage, cause of death, and embolization status. Missing data were excluded from the statistical analysis. The male-to-female ratio was 18:12, with a mean age at first diagnosis of 40.94 ± 13.44 years. Tumor diameters ranged from 1.6 cm to 5.2 cm, with a median of 3.3 cm. There were 3 cystic tumors, 10 solid tumors, and 2 cystic-solid tumors. Tumor origin sites included the cerebellum (18 cases), medulla (8 cases), and multiple locations (3 cases). Surgical resection was total in 24 cases, subtotal in 1 case, and embolization was performed in 4 cases; 23 cases did not undergo embolization. Seven patients (23%) died within one month, with causes of death including hemorrhage, tumor progression, infection, respiratory failure, and unspecified causes. Conclusion: Spontaneous rupture and bleeding of hemangioblastomas are extremely rare, and there is currently insufficient evidence to establish clear treatment guidelines. While surgical resection is considered curative, patients with ruptured and bleeding tumors generally have a worse prognosis. Abbreviations: HB, Hemangioblastoma; VHL, von Hippel-Lindau; CNS, Central nervous system; OS, Overall survival time.

Indexed as

hemangioblastomapreoperative embolizationrecurrencespontaneous hemorrhagesurgical treatment

Identifiers

PMID41717405
PMCPMC12913064

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.